Synonym
Povorcitinib; INCB54707; INCB-54707; INCB 54707;
IUPAC/Chemical Name
(S)-4-(3-(cyanomethyl)-3-(3',5'-dimethyl-1H,1'H-[4,4'-bipyrazol]-1-yl)azetidin-1-yl)-2,5-difluoro-N-(1,1,1-trifluoropropan-2-yl)benzamide
InChi Key
MSGYSFWCPOBHEV-AWEZNQCLSA-N
InChi Code
InChI=1S/C23H22F5N7O/c1-12-20(13(2)33-32-12)15-8-30-35(9-15)22(4-5-29)10-34(11-22)19-7-17(24)16(6-18(19)25)21(36)31-14(3)23(26,27)28/h6-9,14H,4,10-11H2,1-3H3,(H,31,36)(H,32,33)/t14-/m0/s1
SMILES Code
N#CCC(CN1C2=C(C=C(C(N[C@H](C(F)(F)F)C)=O)C(F)=C2)F)(C1)N3C=C(C=N3)C(C(C)=NN4)=C4C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
507.47
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, Santos LL,
Wang A, Bibeau KB, Kimball AB, Porter ML. Efficacy and safety of the oral Janus
kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis
suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-
controlled study. J Am Acad Dermatol. 2024 Mar;90(3):521-529. doi:
10.1016/j.jaad.2023.10.034. Epub 2023 Oct 21. PMID: 37871805.
2: Müller S, Zeidler C, Ständer S. Chronic Prurigo Including Prurigo Nodularis:
New Insights and Treatments. Am J Clin Dermatol. 2024 Jan;25(1):15-33. doi:
10.1007/s40257-023-00818-z. Epub 2023 Sep 17. PMID: 37717255; PMCID:
PMC10796623.
3: Thünemann J, Müller S, Steinbrink K, Ständer S, Zeidler C. Chronic Prurigo. J
Dtsch Dermatol Ges. 2024 Jun;22(6):813-823. doi: 10.1111/ddg.15317. Epub 2024
May 9. PMID: 38722190.
4: Liao V, Cornman HL, Ma E, Kwatra SG. Prurigo nodularis: new insights into
pathogenesis and novel therapeutics. Br J Dermatol. 2024 May 17;190(6):798-810.
doi: 10.1093/bjd/ljae052. PMID: 38345154; PMCID: PMC11099982.
5: Liu H, Santos LL, Smith SH. Modulation of Disease-Associated Pathways in
Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib:
Transcriptomic and Proteomic Analyses of Two Phase 2 Studies. Int J Mol Sci.
2023 Apr 13;24(8):7185. doi: 10.3390/ijms24087185. PMID: 37108348; PMCID:
PMC10139090.
6: Miller A, Shahzeidi P, Bernhardt M. An Update on Current Clinical Management
and Emerging Treatments in Hidradenitis Suppurativa. Skin Therapy Lett. 2024
Mar;29(2):1-6. PMID: 38574201.
7: Heidari A, Ghane Y, Heidari N, Sadeghi S, Goodarzi A. A systematic review of
Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis
suppurativa treatment. Int Immunopharmacol. 2024 Jan 25;127:111435. doi:
10.1016/j.intimp.2023.111435. Epub 2023 Dec 26. PMID: 38150881.
